CEACAM6

CEACAM6, also known as CD66c, belongs to the Carcinoembryonic Antigen (CEA) family, a group of proteins associated with cancer and embryonic development. It is a single-chain glycoprotein comprising an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain includes one or more IgV domains, which are essential for cell-cell adhesion and interactions. It plays a role in various physiological and pathological processes, including immune responses, cell migration, and tumor metastasis, by interacting with other CEACAM proteins on the cell surface. Furthermore, CEACAM6 can also interact with other cell signaling molecules, influencing cellular signal transduction pathways. CEACAM6 has been considered as a cancer biomarker for diagnosis and monitoring disease progression. Additionally, researchers are exploring how to leverage the characteristics of CEACAM6 to develop cancer treatment strategies such as immunotherapy and targeted therapies.

More Interesting read related CEACAM6: a Potent CEA Family Molecule, a New Tumor Marker or Anti-Cancer Target!

Popular Product

Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 6(CEACAM6)(Active) CSB-MP005166HU

Validated Data

SDS

(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

ELISA

Activity: Measured by its binding ability in a functional ELISA. Immobilized Human CEACAM6 at 2 μg/mL can bind Human CEACAM8 (CSB-MP005168HU), the EC₅₀ is 144.7-223.8 ng/mL.

ELISA

Activity: Measured by its binding ability in a functional ELISA. Immobilized Human CEACAM6 at 2 μg/mL can bind Anti- CEACAM5/CEACAM6 recombinant antibody (CSB-RA005165MA2HU), the EC₅₀ is 0.9430-1.377 ng/mL.